


## Product Data Sheet

### Chemical Properties

<b>Product Name:</b>	Meisoindigo
<b>Cas No.:</b>	97207-47-1
<b>M.Wt:</b>	276.29
<b>Formula:</b>	C <sub>17</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub>



<b>Chemical Name:</b>	(3E)-1-methyl-3-(2-oxo-1H-indol-3-ylidene)indol-2-one
<b>Canonical SMILES:</b>	<chem>CN1C2=CC=CC=C2C(=C3C4=CC=CC=C4NC3=O)C1=O</chem>
<b>Solubility:</b>	Soluble in DMSO
<b>Storage:</b>	Store at -20°C
<b>General tips:</b>	For obtaining a higher solubility , please warm the tube at 37° C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20° C for several months.
<b>Shopping Condition:</b>	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

### Biological Activity

<b>Targets :</b>	Apoptosis
<b>Pathways:</b>	Apoptosis Inducers

#### Description:

Meisoindigo is a potential agent for acute myeloid leukemia [1]. Meisoindigo is a synthetic modification of indirubin. It has been used for chronic myeloid leukemia in China with less toxicity. In the in vitro assay, it can inhibit synthesis of DNA and RNA and the assembly of microtubules. It is also reported to have efficacy in acute myeloid leukemia. In the AML cell lines, HL-60, NB4 and U937, meisoindigo induces apoptosis in both caspase-dependent and -independent pathways. The effect induced by meisoindigo is likely

mediated through the intrinsic mitochondrial pathway. Meisoindigo also induces cell cycle arrest with more cells in sub-G1 and G0/G1 phases and fewer cells in the S phase. Besides, meisoindigo is found to induce differentiation in HL-60 and NB4 cell lines. The expression of hTERT can be down-regulated by meisoindigo, which can enhance the anti-leukemic activity of chemotherapeutic agents. Moreover, meisoindigo shows a moderate anti-tumor efficacy in NOD/SCID mice injected with AML cells [1].

**Reference:**

[1] Lee CC, Lin CP, Lee YL, Wang GC, Cheng YC, Liu HE. Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. *Leuk Lymphoma*. 2010 May;51(5):897-905.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

*Specific storage and handling information for each product is indicated on the product datasheet. Most ApexBio products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.*

**ApexBio Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)